X-linked dominant chondrodysplasia punctata with severe phenotype in a female fetus: A case report.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
entrez:
5
1
2019
pubmed:
5
1
2019
medline:
29
1
2019
Statut:
ppublish
Résumé
X-linked dominant chondrodysplasia punctata type 2 (CDPX2) is a condition involving facial, skin, and skeletal dysplasia as a result of a mutation in emopamil binding protein (EBP). It usually presents with mild symptoms in female patients but is fatal in male patients. A fetus was diagnosed with asymmetrical short limbs and a narrow and small thorax by prenatal ultrasound examination at 24+5 weeks gestation. The pregnancy was terminated at 27 weeks of gestation; gross examination, postnatal X-ray and, whole exome analysis were performed to clarify the diagnosis. A provisional diagnosis of fatal skeletal dysplasia was given and the definite diagnosis of CDPX2 was based on postnatal X-ray and genetic testing of the aborted fetus. The pregnancy was terminated at 27 weeks' gestation after a fetal ultrasound indicated a severe abnormal phenotype. Whole exome analysis of aborted tissue confirmed EBP mutation in this case. Unlike most case reports, this female patient presented a severe phenotype that was considered to be related to X-chromosome inactivation. Chondrodysplasia punctata (CDP) should be considered if prenatal ultrasound shows high punctuate echoes at the metaphysis of long bones and asymmetrical short lower limbs. Postnatal X-ray and measurement of sterol levels in the amniotic fluid may aid in the diagnosis of CDP, but the condition can be confirmed with genetic testing of a blood sample or aborted tissue after delivery.
Identifiants
pubmed: 30608402
doi: 10.1097/MD.0000000000013850
pii: 00005792-201901040-00022
pmc: PMC6344186
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13850Références
Hum Genet. 2003 Jan;112(1):78-83
pubmed: 12483303
Am J Med Genet A. 2003 Jan 30;116A(3):255-60
pubmed: 12503102
J Invest Dermatol. 2003 Oct;121(4):939-42
pubmed: 14632217
Am J Med Genet. 2000 Oct 2;94(4):300-5
pubmed: 11038443
Genet Med. 2002 Nov-Dec;4(6):434-8
pubmed: 12509714
Br J Dermatol. 2012 Apr;166(4):830-8
pubmed: 22121851
J Invest Dermatol. 2006 Mar;126(3):638-47
pubmed: 16410790
J Invest Dermatol. 2002 May;118(5):851-8
pubmed: 11982764
Science. 1996 Oct 11;274(5285):255-9
pubmed: 8824192
Hum Mol Genet. 2003 Apr 1;12 Spec No 1:R75-88
pubmed: 12668600
Nat Genet. 1999 Jul;22(3):291-4
pubmed: 10391219
Br J Dermatol. 2012 Jun;166(6):1309-13
pubmed: 22229330
Prenat Diagn. 2015 Jul;35(7):675-84
pubmed: 25754886
Hum Mol Genet. 2000 Aug 12;9(13):1951-5
pubmed: 10942423
JAMA. 2006 Mar 22;295(12):1428-33
pubmed: 16551715